Tiagabine Hydrochloride Tablet, Film Coated
Product Images NDC 0093-5031

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tiagabine Hydrochloride (NDC 0093-5031). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 1)

Chemical structure of Tiagabine Hydrochloride, showing its molecular framework including thiophene rings and a piperidine ring with a carboxyl functional group, associated with hydrochloride.*

FDA Label Image

Tiagabine Hydrochloride Tablets 2 mg, 30s Label (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 10)

Tiagabine Hydrochloride Tablets 2 mg film-coated oral tablets label by Teva Pharmaceuticals USA, Inc. The label shows drug name, strength, quantity of 30 tablets, NDC 0093-5030-56, and usage instruction that a medication guide is required. It includes manufacturing details and a barcode on the right.*

FDA Label Image

Tiagabine Hydrochloride Tablets 4 mg, 30s Label (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 11)

Label for Tiagabine Hydrochloride Tablets 4 mg by Teva Pharmaceuticals USA, Inc. The film-coated oral tablets come in a package of 30. The label includes a medication guide notice, serialization coding area, NDC 0093-5031-56, barcode, and manufacturing details specifying Parsippany, NJ, and Malta.*

FDA Label Image

Tiagabine Hydrochloride Tablets 12 mg, 30s Label (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 12)

Tiagabine Hydrochloride Tablets 1.2 mg film-coated tablets package label by Teva Pharmaceuticals USA, Inc. The label includes the product name, strength, dosage form, and quantity of 30 tablets. The label features NDC 0093-8072-56 and mentions medication guide requirements and dispensing instructions. A barcode is present on the right side.*

FDA Label Image

Tiagabine Hydrochloride Tablets 16 mg, 30s Label (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 13)

Label for Tiagabine Hydrochloride Tablets 16 mg by Teva Pharmaceuticals USA, Inc. The film-coated oral tablets are provided in a package of 30 tablets. The label includes instructions for medication guide dispensing, the NDC number 0093-8076-56, and a barcode.*

FDA Label Image

Figure01 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 2)

A cumulative frequency chart showing the percentage reduction in partial seizure rate for patients treated with Tiagabine Hydrochloride 32 + 56 mg/day compared to placebo. The y-axis represents percent reduction in partial seizure rate, ranging from -250% worsening to 100% improvement. The x-axis represents percent of patients. Tiagabine shows better outcomes with higher rates of seizure reduction compared to placebo.*

FDA Label Image

Figure02 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 3)

A cumulative distribution plot depicting percent reduction in partial seizure rate versus percent of patients for Tiagabine Hydrochloride at doses 16 mg/day, 32 mg/day, 56 mg/day, and placebo. The vertical axis ranges from -250% to 100% reduction, with labels indicating improvement and worsening, and the horizontal axis represents the percentage of patients from 0 to 100.*

FDA Label Image

Figure03 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 4)

A cumulative distribution plot displaying the percentage reduction in partial seizure rate versus percentage of patients. The graph compares three treatment groups: placebo, Tiagabine Hydrochloride 8 mg QID, and Tiagabine Hydrochloride 16 mg BID. The vertical axis indicates improvement and worsening in seizure rate, while the horizontal axis represents patient percentages.*

FDA Label Image

Figure04 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 5)

A cumulative distribution plot showing percentage reduction in partial seizure rate for patients treated with Tiagabine Hydrochloride 10 mg TID compared to placebo. The x-axis represents the percentage of patients, and the y-axis depicts the reduction in seizure rate, ranging from worsening to improvement.*

FDA Label Image

Figure05 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 6)

FDA Label Image

Figure06 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 7)

Chemical structure diagram of Tiagabine Hydrochloride, a prescription drug. The image shows the molecular arrangement with labeled atoms and bonds representing the compound's chemical composition.*

FDA Label Image

Image07 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 8)

Tiagabine Hydrochloride 2 mg film-coated tablets in a blister pack. The image shows a silver-colored, foil-backed blister card containing ten tablets arranged in two rows of five. Markings on the foil indicate strength and manufacturer, Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image08 (Tiagabine HCl Tablets 2 mg 4 mg 12 mg 16 mg 9)

Tiagabine Hydrochloride 2 mg film-coated tablets in a blister card. The foil backing displays individual tablet compartments with printed text including strength and manufacturing details. The labeler is Teva Pharmaceuticals USA, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.